BUZZ-First Tracks Biotherapeutics stock rises after completing $200 million equity financing
路透社2026/10/15 12:41October 15 - ** First Tracks Biotherapeutics (TRAX.O) shares rose 2.8% pre-market on Thursday to $35.08 after the company completed a $200 million equity financing
** TRAX stated that (link) it sold approximately 6.1 million shares to groups of new and existing investors through a private placement at $32.75 per share
** The company plans to use the net proceeds from this offering for general corporate purposes, including clinical development of ANB033
** Leerink, Piper Sandler, UBS, and Wells Fargo served as the underwriters for this placement
** On Monday, TRAX shares closed up about 7% at $34.05 after the company (link) announced positive initial results from an ANB033 drug trial for celiac disease
** The company, headquartered in San Diego, California, has about 35.7 million shares outstanding
** On April 20, TRAX debuted on Nasdaq with a closing price of $18.60 after being spun out from AnaptysBio ANAB.O (link)
** All 12 analysts covering TRAX have a bullish outlook, with 4 rating it "strong buy"; according to London Stock Exchange Group (LSEG) data, the stock's median target price is $70, up from $44 three months ago
(To facilitate non-native English speakers, Reuters provides automated translation of its reports into several other languages. As automated translation may contain inaccuracies or lack context, Reuters does not guarantee the accuracy of these translations and provides them for reader convenience only. Reuters accepts no liability for any harm or loss arising from the use of automated translation functions.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Crypto prices
More
